ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ORIC Pharmaceuticals (ORIC) reported initial Phase 1 dose-escalation results for ORIC-533 in relapsed or refractory multiple myeloma on December 11, 2023.
As of November 28, 2023, 23 patients had received 400 mg to 2400 mg once daily; all were triple-class refractory and 91% were penta-refractory. Treatment-related adverse events were limited to Grades 1 and 2, with no dose-limiting toxicities, dose reductions or treatment-related serious adverse events. One patient had a confirmed minor response. Reductions in soluble BCMA, a blood marker associated with myeloma activity, were observed at the 1600 mg dose. A majority of patients given at least 1200 mg showed increased activation of immune cells.
ORIC intends to finish dose escalation in the first quarter of 2024. It plans to pursue combination studies only with a future partner's operational and financial backing. The company projects its cash runway into 2026 while prioritizing ORIC-114 and ORIC-944.
Summary not available.
Summary not available.
Summary not available.